Primary Blastic Plasmacytoid Dendritic Cell Neoplasm: a US Population-Based Study

Fan Wang

doi:10.1101/2023.01.05.23284215

Abstract

Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and poorly understood hematopoietic malignancy. This study aimed to investigate the clinical characteristics and prognostic factors in patients with primary BPDCN.

Methods Patients diagnosed with primary BPDCN from 2000 to 2019 were extracted from the Surveillance, Epidemiology and End Results (SEER) database. Independent prognostic factors were evaluated based on the univariate and multivariate Cox regression analysis. The nomogram was then constructed to predict the overall survival of primary BPDCN patients at 3, 5 and 10 years after diagnosis.

Results A total of 668 primary BPDCN patients were included in this study. The average age was 35.7 ± 25.4 years, with 68.7% being male. The mostly affected sites were lymph nodes (59.9%). Most patients (69.9%) received chemotherapy or radiation therapy. For all the patients, the 1-year, 3-year, 5-year, and 10-year overall survival (OS) were 78.0%, 62.6%, 59.0%, and 56.3%, respectively, and the corresponding disease-specific survival (DSS) were 80.6%, 66.8%, 63.5, and 61.8%, respectively. Multivariate cox analysis indicated that age and marital status of other (divorced, widowed and separated) at diagnosis were independent prognostic factors for DSS, but only age was for OS. The 5-year OS rate significantly declined with increasing age: age <15, 89.3%; age 15-39, 57.9%; age 40-64, 51.2%; age ≥65, 26.1%. Nomograms were further constructed to predict the possibility of OS and DSS with good performances.

Conclusions Primary BPDCN is a rare disease, age and marital status were associated with survival of primary BPDCN patients, and age was an independent prognostic factor for OS.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Natural Science Foundation of China, No. 82070174.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes